

**URGENT**  
**PRESS RELEASE**



**Wockhardt Limited**  
Wockhardt Towers  
Bandra Kurla Complex  
Bandra (East), Mumbai 400 051, India  
Tel.: +91 22 2653 4444  
Fax: +91 22 2653 4242  
Website: [www.wockhardt.com](http://www.wockhardt.com)

---

## Wockhardt's Q4 Results 2009

Consolidated Sales: Rs. 889 crore  
Operating Profits: Rs 134 crore  
Wockhardt's UK & India branded business posts double-digit growth

Mumbai, 25 Jan,2010

Pharmaceutical and biotechnology major Wockhardt Limited today announced its fourth quarter results for the quarter ending December 31, 2009. Consolidated sales revenues stood at Rs. 889 crore. Operating profit (EBIDTA) was Rs. 134 crore. Due to exceptional items, the net loss is Rs. 181 crore.

### India Business:

As per ORG-IMS, Wockhardt's India branded business grew by 23% in the fourth quarter of 2009 over the corresponding period of 2008. There were 2 new products launched during this period in the large volume markets of Non Steroidal Anti-Inflammatory Drugs (Pain Management) and Azithromycin antibiotic. Overall 10 brands featured in the list of 'Top 300' brands of the industry with 2 brands in the 'Top 100'. Wockhardt's Power Brands are showing good consistent growth.

### Europe Business:

Wockhardt UK grew by 21% compared to the industry growth of only 4% in Q4-2009. Growth drivers being Hospital products that grew by 16% and exports by 38%. Pinewood Healthcare in Ireland maintains steady sales showing a growth of more than 8% in exports. Negma Laboratories' cardio-vascular brand, Nebilox grew by 25% and it has also entered into a sales & marketing collaboration with Novartis on 2 products – Voltarene (Pain Management) and Eucreas (DPP-IV inhibitor for Diabetes Management).

### USA Business:

Wockhardt USA received 5 ANDA approvals in the fourth quarter of 2009, of which 1 ANDA approval was for an injectible. Wockhardt's US FDA approved Nicardipine Injection was a 1st Day launch. In many instances, Wockhardt has first-to-file ANDA status and such filings are a critical growth factor in the highly competitive US generic market. Wockhardt's US Paediatric Business is growing consistently and gaining a good market share amongst the targeted physicians. Wockhardt currently markets 74 products in the US.

#### About Wockhardt

Wockhardt is a technology-driven global pharmaceutical and biotechnology major with an innovative multi-disciplinary research and development programme. It has 5 research centres with over 500 scientists and 14 world-class manufacturing plants dotting various countries. Wockhardt's manufacturing plants are compliant to international regulatory standards such as the US FDA, MHRA and other global regulatory bodies. It has end-to-end integrated capabilities for its products, right from development and manufacture of the oral and sterile API's to manufacturing of formulation dosage forms as well as marketing of these products through its various business divisions. Wockhardt has a global footprint including the US, UK, Ireland and France with a multi-ethnic workforce from 14 different nationalities.

---

**For more information, visit [www.wockhardt.com](http://www.wockhardt.com)  
Corporate Relations Department**